Glenmark Pharmaceuticals Ltd is up for a third straight session in a row. The stock is quoting at Rs 393.95, up 1.27% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.22% on the day, quoting at 17697.8. The Sensex is at 59458.94, up 0.21%. Glenmark Pharmaceuticals Ltd has gained around 2.14% in last one month.

Meanwhile, Nifty Metal index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 2.34% in last one month and is currently quoting at 13014.2, down 0.75% on the day. The volume in the stock stood at 15.06 lakh shares today, compared to the daily average of 11.61 lakh shares in last one month.

The benchmark August futures contract for the stock is quoting at Rs 395.6, up 1.22% on the day. Glenmark Pharmaceuticals Ltd is down 30.06% in last one year as compared to a 7.07% jump in NIFTY and a 8.06% jump in the Nifty Metal index.

The PE of the stock is 6.68 based on TTM earnings ending March 22.

Powered by Capital Market - Live News

Net profit of Glenmark Pharmaceuticals declined 37.20% to Rs 192.53 crore in the quarter ended June 2022 as against Rs 306.56 crore during the previous quarter ended June 2021. Sales declined 7.67% to Rs 2720.10 crore in the quarter ended June 2022 as against Rs 2946.15 crore during the previous quarter ended June 2021.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 10 August 2022.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (U.S. FDA) for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg/20 mcg, the generic version of Taytulla®1 Capsules, of Allergan Pharmaceuticals International.

According to IQVIATM sales data for the 12 month period ending May 2022, the Taytulla® Capsules market achieved annual sales of approximately $85.9 million.

Powered by Capital Market - Live News